Back to Search Start Over

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

Authors :
Antonio Bertolotto
Michela Spadaro
Alessandra Lugaresi
Marzia Caldano
Fabiana Marnetto
Spadaro, Michela
Caldano, Marzia
Marnetto, Fabiana
Lugaresi, Alessandra
Bertolotto, Antonio
Source :
Journal of Neuroinflammation
Publication Year :
2015

Abstract

Background The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4+ T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been suggested in multiple sclerosis (MS) patients treated with NTZ. Methods We performed a flow cytometric analysis on peripheral blood mononuclear cells (PBMC); we collected from 23 healthy donors and 225 MS patients: untreated (n = 19) or treated with NTZ (n = 113), interferon-beta (n = 26), glatiramer acetate (n = 26), fingolimod (n = 23) and rituximab (n = 18). We have also analysed two PML/IRIS (immune reconstitution inflammatory syndrome) patients and four longitudinal samples of a NTZ-treated patients before and during the development of a clinical asymptomatic magnetic resonance imaging (MRI) lesion confirmed as PML by cerebrospinal fluid (CSF) examination. Thirty-five NTZ-treated patients were studied longitudinally with three samples taken 4 months apart. Results The NTZ-treated patients showed a lower percentage of CD62L (33.68 %, n = 113) than first-line treated patients (44.24 %, n = 52, p = 0.0004). NTZ effect was already clear during the first year of treatment (34.68 %; p = 0.0184); it persisted in the following years and disappeared after drug withdrawal (44.08 %). Three percent of longitudinally analysed patients showed a percentage of CD62LCD4+ T cells under a hypothetical threshold and one patient with asymptomatic PML belongs to a group which expressed low percentage of CD62LCD4+ T cells. Conclusions Our research confirms that NTZ has a specific effect on CD62LCD4+ T cells consisting in decreasing of the number of positive cells. The low level of CD62L found in a clinically asymptomatic PML patient strengthens its potential usefulness as a biomarker of high PML risk in NTZ-treated patients. A larger study is required to better confirm the data. Electronic supplementary material The online version of this article (doi:10.1186/s12974-015-0365-x) contains supplementary material, which is available to authorized users.

Details

ISSN :
17422094
Volume :
12
Database :
OpenAIRE
Journal :
Journal of neuroinflammation
Accession number :
edsair.doi.dedup.....c4141bd878bda00216fbab7aa83b20da